Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 22257673

Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Lancet
Publication date
2012 Feb 18
First author
Baselga J

This record carries publication-notice metadata. Review the notices below before relying on it.

Publication notices

absence is not clearance
true
has correction metadata
true
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet. 2012 Feb 18;379(9816):616
    note
    Dosage error in published abstract; MEDLINE/PubMed abstract corrected
    related pmid
    Source null
    relationship
    Erratum in
    url
    Source null
  2. citation
    Lancet. 2012 Feb 18;379(9816):596-8. doi: 10.1016/S0140-6736(12)60068-3.
    note
    Source null
    related pmid
    22257672
    relationship
    Comment in
  3. citation
    Lancet. 2012 Jun 16;379(9833):2237; author reply 2238. doi: 10.1016/S0140-6736(12)60970-2.
    note
    Source null
    related pmid
    22704160
    relationship
    Comment in
  4. citation
    Lancet. 2012 Jun 16;379(9833):2237; author reply 2238. doi: 10.1016/S0140-6736(12)60971-4.
    note
    Source null
    related pmid
    22704161
    relationship
    Comment in

Authors and identifiers

  1. name
    Baselga J
    type
    Author
  2. name
    Bradbury I
    type
    Author
  3. name
    Eidtmann H
    type
    Author
  4. name
    Di Cosimo S
    type
    Author
  5. name
    de Azambuja E
    type
    Author
  6. name
    Aura C
    type
    Author
  7. name
    Gómez H
    type
    Author
  8. name
    Dinh P
    type
    Author
  9. name
    Fauria K
    type
    Author
  10. name
    Van Dooren V
    type
    Author
  11. name
    Aktan G
    type
    Author
  12. name
    Goldhirsch A
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Baselga J
    type
    Author
  2. name
    Bradbury I
    type
    Author
  3. name
    Eidtmann H
    type
    Author
  4. name
    Di Cosimo S
    type
    Author
  5. name
    de Azambuja E
    type
    Author
  6. name
    Aura C
    type
    Author
  7. name
    Gómez H
    type
    Author
  8. name
    Dinh P
    type
    Author
  9. name
    Fauria K
    type
    Author
  10. name
    Van Dooren V
    type
    Author
  11. name
    Aktan G
    type
    Author
  12. name
    Goldhirsch A
    type
    Author
bibliography ids
  1. nci-bib-dbf009be78765afd698abadf
book metadata
content sha256
d8ba0a293e7db768ccf5ca57c1984be7989c477336ec9eab9d83a7dde04cc3b2
document type
citation
dois
  1. 10.1016/S0140-6736(11)61847-3
electronic publication date
display
2012 Jan 17
precision
day
year
2012
evidence scope
bibliographic_metadata_only
id
pubmed:22257673
immutable id
pubmed:22257673@d8ba0a293e7db768ccf5ca57c1984be7989c477336ec9eab9d83a7dde04cc3b2
journal
abbreviation
Lancet
issn electronic
1474-547X
issn print
0140-6736
issue
9816
name
Lancet (London, England)
nlm unique id
2985213R
pages
633-40
volume
379
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
true
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet. 2012 Feb 18;379(9816):616
    note
    Dosage error in published abstract; MEDLINE/PubMed abstract corrected
    related pmid
    Source null
    relationship
    Erratum in
    url
    Source null
  2. citation
    Lancet. 2012 Feb 18;379(9816):596-8. doi: 10.1016/S0140-6736(12)60068-3.
    note
    Source null
    related pmid
    22257672
    relationship
    Comment in
  3. citation
    Lancet. 2012 Jun 16;379(9833):2237; author reply 2238. doi: 10.1016/S0140-6736(12)60970-2.
    note
    Source null
    related pmid
    22704160
    relationship
    Comment in
  4. citation
    Lancet. 2012 Jun 16;379(9833):2237; author reply 2238. doi: 10.1016/S0140-6736(12)60971-4.
    note
    Source null
    related pmid
    22704161
    relationship
    Comment in
outcomes validated
false
pmid
22257673
provenance
batch id
b6284687e167e7da9556
provider
NCBI PubMed ESummary
record sha256
7907004ff725f07da9e350b72f49c48e0b46ec091d5afdc41518f576809e631f
response sha256
64d5b7bb63f574c559af2523b779a262267cbc8e8cd02a5b47f4193cc95cabd3
retrieved at
2026-09-09T23:46:45.216259+00:00
publication date
display
2012 Feb 18
precision
day
year
2012
publication types
  1. Clinical Trial, Phase III
  2. Journal Article
  3. Multicenter Study
  4. Randomized Controlled Trial
  5. Research Support, Non-U.S. Gov't
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/22257673/
title
Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial.

Preserved source evidence · Not medical advice